Zoledronic Acid CAS 118072-93-8 Mimọ ≥99.7% API Didara Giga Ile-iṣẹ
Ipese pẹlu Iwa mimọ giga ati Didara Idurosinsin
Orukọ Kemikali: Zoledronic Acid
CAS: 118072-93-8
Agbara Farnesyl Diphosphate (FPP) Inhibitor Synthase
API Didara Giga, Iṣelọpọ Iṣowo
| Orukọ Kemikali | Zoledronic Acid |
| Awọn itumọ ọrọ sisọ | ZOL 446, ZA, Zoledronate, CGP-4244, GP42446A, Zometa, Zomera;[1-Hydroxy-2- (1H-imidazol-1-yl)-ethylidene] bisphosphonic acid. |
| Nọmba CAS | 118072-93-8 |
| NỌMBA CAT | RF-API90 |
| Iṣura Ipo | Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn ọgọọgọrun Kilogram |
| Fọọmu Molecular | C5H10N2O7P2 |
| Òṣuwọn Molikula | 272.09 |
| Ojuami Iyo | 193.0 ~ 204.0 ℃ |
| Brand | Ruifu Kemikali |
| Nkan | Awọn pato |
| Ifarahan | Funfun lati Pa-White Crystalline Powder |
| Idanimọ | IR Spectrum ti ayẹwo ni ibamu si ti boṣewa itọkasi |
| pH | 2.0 ~ 4.0 |
| Solubility | Solublely Soluble ni Solusan Sodium Hydroxide 0.1N, Itukutu die-die ninu Omi ati 0.1N Hydrochloric Acid, Aifọwọyi Ni Ethanol |
| Awọn nkan ti o jọmọ | |
| Eyikeyi Olukuluku aimọ | ≤0.10% |
| Lapapọ Awọn Aimọ | ≤0.30% |
| Pipadanu lori Gbigbe | 5.0% ~ 7.0% |
| Kloride | ≤0.02% |
| Fọsifiti | ≤0.50% |
| Phosphate | ≤0.50% |
| Awọn irin Heavy | ≤10ppm |
| Mimo | ≥99.7% |
| Igbeyewo Standard | Standard Enterprise |
| Lilo | API, FPP Synthase Inhibitor, Hypercalcemia ti Ibajẹ (HCM) |
Package: Igo, apo apamọwọ Aluminiomu, ilu paali, 25kg / Drum, tabi gẹgẹbi ibeere alabara.
Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina, ọrinrin ati kokoro infestation.
Zoledronic Acid (CAS 118072-93-8) jẹ bisphophonate farnesyl diphosphate (FPP) inhibitor synthase ti o lagbara (IC50=20 nM).Idilọwọ awọn isọdọtun egungun ti o ni ilaja osteoclast.Tun ṣe idiwọ ifihan agbara Ras ati idagbasoke tumo, ati pe o fa apoptosis ni awọn sẹẹli alakan pancreatic.Yipada iyipada epithelial-mesenchymal ati idilọwọ isọdọtun sẹẹli alakan igbaya nipasẹ aiṣiṣẹ ti NF-κB.Zoledronic acid ti fọwọsi nipasẹ US FDA ni ọdun 2001 fun itọju hypercalcemia ti ibajẹ, ilolu ti iṣelọpọ ti o le jẹ eewu-aye.Hypercalcemia ti ibajẹ le waye ni to 50% ti awọn alaisan ti o ni ayẹwo pẹlu akàn igbaya ti o ti ni ilọsiwaju, ọpọ myeloma, ati akàn ẹdọfóró sẹẹli ti kii ṣe kekere.Ipo yii nwaye nigbati awọn nkan kemika ti a ṣe nipasẹ tumo fa arugbo ti osteoclasts.Nigbati ilosoke ninu ibajẹ eegun ba wa, itusilẹ lẹẹkọọkan ti kalisiomu wa sinu pilasima.Nigbati awọn ifọkansi omi ara ti kalisiomu ga soke, awọn kidinrin ko lagbara lati mu iwọn apọju, ati awọn abajade hypercalcemia.Zoledronic acid ni imunadoko dinku awọn ifọkansi kalisiomu pilasima nipasẹ idinamọ ti isọdọtun egungun (idinamọ iṣẹ ṣiṣe osteoclastic ati ifilọlẹ ti apoptosis osteoclast).Ni afikun zoledronic acid ti ni ifọwọsi nipasẹ US FDA fun itọju ọpọ myeloma ati awọn metastases egungun ti o ni nkan ṣe pẹlu awọn aarun ti o da lori tumo (fun apẹẹrẹ, iforibalẹ ati ẹdọfóró).
